Add-on to Cognitive, Event-Related Potentials (ERP) and Electroencephalogram (EEG) Asymmetry in Affective Disorders

New York State Psychiatric Institute

Overview

Depressed patients unremitted after monotherapy with citalopram or bupropion will remit following six weeks treatment with the combination of citalopram and bupropion.

Participants in another study who did not remit during 12 weeks treatment with citalopram (to 40 mg/d) or bupropion (to 450 mg/d) will have citalopram (to 40 mg/d) or bupropion (to 450 mg/d) added for six weeks.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Depressive Illness

Interventions

bupropionDRUG

FDA approved drug for treating depression

citalopramDRUG

FDA approved treatment for depression

Eligibility

Sex: ALLMin age: 18 YearsMax age: 66 Years

Medical Language ↔ Plain English

Inclusion Criteria: * non-remission in Protocol #6559R * age 18-66 * signs informed consent * physically healthy Exclusion Criteria: * bipolar disorder * history of psychosis * history of anorexia nervosa or bulimia * history of seizure disorder, significant brain trauma or other medical reason to suspect increased seizure risk

Locations (1)

New York State Psychiatric Institute

New York, New York, United States

Outcomes

Primary Outcomes

Hamilton Rating Scale

Decrease in score for Hamilton Rating Scale for Depression, 17-item version

Time frame: weeks 6

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.